Press Release

BIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer’s Disease at the RNA Leaders USA Conference in Boston

Back to list BIORCHESTRA Announces that its Proprietary Compound, BMD-001, Reduces Amyloid-β and Tau Inflammatory Symptoms in Primate Models for Alzheimer's Disease at the RNA Leaders USA Conference Boston, MA,…

Continue ReadingBIORCHESTRA announces that BMD-001 reduces Amyloid-β and Tau in non-human primate animal model of Alzheimer’s Disease at the RNA Leaders USA Conference in Boston

BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology

Back to list BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel Helmlinger (Ph.D., D.A.B.T.) as Vice-President, Head…

Continue ReadingBIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology

BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer’s disease and drug delivery system technology at the 2022 BIO International Convention

Back to list BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer's disease and drug delivery system technology at the 2022 BIO International Convention BIORCHESTRA Co., Ltd (BIORCHESTRA), is scheduled to give…

Continue ReadingBIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer’s disease and drug delivery system technology at the 2022 BIO International Convention